2-deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Yao, Jia ^a   Chen, Shuhua ^a   Mao, Zisu ^a   Cadenas, Enrique ^a   Brinton, Roberta Diaz ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DEOXYGLUCOSE; GAMMA SECRETASE; KETONE; KETONE BODY; NERVE GROWTH FACTOR; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENERGY; BRAIN NERVE CELL; BRAIN TISSUE; CLEARANCE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; EMBRYO; FATTY ACID BLOOD LEVEL; FEMALE; HIPPOCAMPUS; KETOGENESIS; MITOCHONDRIAL RESPIRATION; MOUSE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; BRAIN; DIET THERAPY; DISEASE MODEL; DRUG EFFECT; ENERGY METABOLISM; GENETICS; METABOLISM; MITOCHONDRION; NERVE CELL; PATHOLOGY; UPREGULATION;

MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DEOXYGLUCOSE; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FEMALE; KETONE BODIES; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NERVE GROWTH FACTORS; NEURONS; OXIDATIVE STRESS; UP-REGULATION;

EID: 79959802475     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021788     Document Type: Article

References (59)

1. Brinton RD, (2008) Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv Drug Deliv Rev 60: 1504-1511.
2. Magistretti PJ, (2006) Neuron-glia metabolic coupling and plasticity. J Exp Biol 209: 2304-2311.
3. Wallace DC, (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 39: 359-407.
4. Swerdlow RH, (2009) The neurodegenerative mitochondriopathies. J Alzheimers Dis 17: 737-751.
5. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, et al. (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 36: 811-822.
6. Moreira PI, Zhu X, Wang X, Lee HG, Nunomura A, et al. (2010) Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 1802: 212-220.
7. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, et al. (2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 106: 14670-14675.
8. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, et al. (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304: 448-452.
9. Takuma K, Yao J, Huang J, Xu H, Chen X, et al. (2005) ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 19: 597-598.
10. Mosconi L, De Santi S, Li J, Tsui WH, Li Y, et al. (2008) Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 29: 676-692.
11. Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, et al. (1997) Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J Nucl Med 38: 925-928.
12. Chen K, Ayutyanont N, Langbaum JB, Fleisher AS, Reschke C, et al. (2011) Characterizing Alzheimer's disease using a hypometabolic convergence index. NeuroImage.
13. Blass JP, Sheu RK, Gibson GE, (2000) Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Ann N Y Acad Sci 903: 204-221.
14. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, et al. (2004) Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proceedings of the National Academy of Sciences of the United States of America 101: 2173-2178.
15. Miller JA, Oldham MC, Geschwind DH, (2008) A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. The Journal of neuroscience: the official journal of the Society for Neuroscience 28: 1410-1420.
16. Hoyer S, (1991) Abnormalities of glucose metabolism in Alzheimer's disease. Ann N Y Acad Sci 640: 53-58.
17. Yao J, Hamilton RT, Cadenas E, Brinton RD, (2010) Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Biochim Biophys Acta 1800: 1121-1126.
18. Morris AA, (2005) Cerebral ketone body metabolism. J Inherit Metab Dis 28: 109-121.
19. Gasior M, Rogawski MA, Hartman AL, (2006) Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol 17: 431-439.
20. Guzman M, Blazquez C, (2004) Ketone body synthesis in the brain: possible neuroprotective effects. Prostaglandins Leukot Essent Fatty Acids 70: 287-292.
21. Ralser M, Wamelink MM, Struys EA, Joppich C, Krobitsch S, et al. (2008) A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth. Proc Natl Acad Sci U S A 105: 17807-17811.
22. Yu ZF, Mattson MP, (1999) Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J Neurosci Res 57: 830-839.
23. Duan W, Mattson MP, (1999) Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J Neurosci Res 57: 195-206.
24. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, et al. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421.
25. Brinton RD, (2008) The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci 31: 529-537.
26. Costantini LC, Barr LJ, Vogel JL, Henderson ST, (2008) Hypometabolism as a therapeutic target in Alzheimer's disease. BMC Neurosci 9 (Suppl 2): S16.
27. Auestad N, Korsak RA, Morrow JW, Edmond J, (1991) Fatty acid oxidation and ketogenesis by astrocytes in primary culture. J Neurochem 56: 1376-1386.
28. Reddy PH, Manczak M, Mao P, Calkins MJ, Reddy AP, et al. (2010) Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J Alzheimers Dis 20 (Suppl 2): S499-512.
29. Santos RX, Correia SC, Wang X, Perry G, Smith MA, et al. (2010) Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. Int J Clin Exp Pathol 3: 570-581.
30. Yan SD, Stern DM, (2005) Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD). Int J Exp Pathol 86: 161-171.
31. Cadenas E, (2004) Mitochondrial free radical production and cell signaling. Mol Aspects Med 25: 17-26.
32. Shepherd JD, Bear MF, (2011) New views of Arc, a master regulator of synaptic plasticity. Nature neuroscience 14: 279-284.
33. Ramirez-Amaya V, Vazdarjanova A, Mikhael D, Rosi S, Worley PF, et al. (2005) Spatial exploration-induced Arc mRNA and protein expression: evidence for selective, network-specific reactivation. The Journal of neuroscience: the official journal of the Society for Neuroscience 25: 1761-1768.
34. Beal MF, (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58: 495-505.
35. Soane L, Kahraman S, Kristian T, Fiskum G, (2007) Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. J Neurosci Res 85: 3407-3415.
36. Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, et al. (2010) Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc Natl Acad Sci U S A 107: 17763-17767.
37. Vaishnavi SN, Vlassenko AG, Rundle MM, Snyder AZ, Mintun MA, et al. (2010) Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci U S A 107: 17757-17762.
38. Laferla FM, Green KN, Oddo S, (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8: 499-509.
39. Corona C, Frazzini V, Silvestri E, Lattanzio R, La Sorda R, et al. (2011) Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice. PloS one 6: e17971.
40. Wang J, Ho L, Zhao Z, Seror I, Humala N, et al. (2006) Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 20: 2313-2320.
41. Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, et al. (2009) Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. The Journal of neuroscience: the official journal of the Society for Neuroscience 29: 1977-1986.
42. Fischer PM, (2008) Turning down tau phosphorylation. Nat Chem Biol 4: 448-449.
43. Patel NV, Gordon MN, Connor KE, Good RA, Engelman RW, et al. (2005) Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiology of aging 26: 995-1000.
44. Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, et al. (2007) Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiology of disease 26: 212-220.
45. Wang J, Ho L, Qin W, Rocher AB, Seror I, et al. (2005) Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 19: 659-661.
46. Lee J, Duan W, Long JM, Ingram DK, Mattson MP, (2000) Dietary restriction increases the number of newly generated neural cells, and induces BDNF expression, in the dentate gyrus of rats. Journal of molecular neuroscience: MN 15: 99-108.
47. Duan W, Guo Z, Jiang H, Ware M, Li XJ, et al. (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proceedings of the National Academy of Sciences of the United States of America 100: 2911-2916.
48. Duan W, Lee J, Guo Z, Mattson MP, (2001) Dietary restriction stimulates BDNF production in the brain and thereby protects neurons against excitotoxic injury. Journal of molecular neuroscience: MN 16: 1-12.
49. Maalouf M, Rho JM, Mattson MP, (2009) The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain research reviews 59: 293-315.
50. Sreekumar R, Unnikrishnan J, Fu A, Nygren J, Short KR, et al. (2002) Effects of caloric restriction on mitochondrial function and gene transcripts in rat muscle. American journal of physiology Endocrinology and metabolism 283: E38-43.
51. Frier B, Locke M, (2005) Preservation of heat stress induced myocardial hsp 72 in aged animals following caloric restriction. Experimental gerontology 40: 615-617.
52. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, et al. (1996) Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. International journal of radiation oncology, biology, physics 35: 103-111.
53. Dwarakanath BS, Singh D, Banerji AK, Sarin R, Venkataramana NK, et al. (2009) Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. Journal of cancer research and therapeutics 5 (Suppl 1): S21-26.
54. Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, et al. (2010) Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. The Prostate 70: 1388-1394.
55. Marsh J, Mukherjee P, Seyfried TN, (2008) Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutrition & metabolism 5: 33.
56. Kern KA, Norton JA, (1987) Inhibition of established rat fibrosarcoma growth by the glucose antagonist 2-deoxy-D-glucose. Surgery 102: 380-385.
57. Wan R, Camandola S, Mattson MP, (2004) Dietary supplementation with 2-deoxy-D-glucose improves cardiovascular and neuroendocrine stress adaptation in rats. American journal of physiology Heart and circulatory physiology 287: H1186-1193.
58. Minor RK, Smith DL Jr, Sossong AM, Kaushik S, Poosala S, et al. (2010) Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and increases mortality in rats. Toxicology and applied pharmacology 243: 332-339.
59. Irwin RW, Yao J, Hamilton RT, Cadenas E, Brinton RD, et al. (2008) Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology 149: 3167-3175.